Allergy Therapeutics plc (LON:AGY – Get Free Report) shares reached a new 52-week low during trading on Thursday . The company traded as low as GBX 4.50 and last traded at GBX 4.82, with a volume of 79453 shares traded. The stock had previously closed at GBX 4.75.
Allergy Therapeutics Trading Up 1.5%
The company has a market capitalization of £305.23 million, a P/E ratio of -4.97, a PEG ratio of -30.70 and a beta of 0.83. The business has a 50 day moving average price of GBX 5.45 and a 200 day moving average price of GBX 7.93. The company has a current ratio of 1.13, a quick ratio of 1.48 and a debt-to-equity ratio of 629.58.
Allergy Therapeutics Company Profile
Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development.
See Also
- Five stocks we like better than Allergy Therapeutics
- Hims & Hers Slides Nearly 7% as Legal Pressure Adds to Its Growing List of Risks
- Paychex Plunges, Providing the Entry Investors Have Been Waiting For
- The Case for Buying High-Yield General Mills Just Strengthened
- SanDisk’s $1,800 Breakout Turns Memory Hardware Into a Profit Story
Receive News & Ratings for Allergy Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergy Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
